Uzbekistan Pharmaceutical Safety Center: Additional Monitoring of Medicines — 29 July 2026
- 29-07-2026
- Posted by: Eldaniz Hasanov
- Category: Regulatory Updates
No Comments
Medium importance
Uzbekistan · Center for Pharmaceutical Product Safety · 29 July 2026
Uzbekistan Pharmaceutical Safety Center: additional monitoring of medicines
The Center for Pharmaceutical Product Safety of Uzbekistan published a revised notice prepared in accordance with Chapter 14 of the national standard O‘z MSt 339:2024 “Good Pharmacovigilance Practices (GVP)”.
Why this matters
The notice directly concerns additional monitoring, information in medicine instructions and prompt reporting of adverse reactions.
The notice directly concerns additional monitoring, information in medicine instructions and prompt reporting of adverse reactions.
Confirmed information
- Product information for medicines subject to additional monitoring should display a prominent black inverted triangle ▼.
- Unexpected adverse reactions should be reported promptly through the pharmacovigilance system.
- The symbol indicates systematic collection of additional medicine-safety data.
Official source
Center for Pharmaceutical Product Safety of Uzbekistan — Additional monitoring of medicines